Key Takeaways CorMedix launched DefenCath in 2024, generating $78.8M in H1 2025 revenues and raising guidance.CRMD acquired Melinta for $300M, adding seven marketed therapies and diversifying beyond DefenCath.MIRM's Livmarli posted $161.4M H1 2025 sales, but revenue reliance and competition pose key risks.CorMedix (CRMD) and Mirum Pharmaceuticals (MIRM) are pursuing treatments for underserved medical conditions where existing therapies are limited or nonexistent. Both companies are carving out niches in are ...

公司核心业务 - CorMedix是一家生物技术公司 专注于开发和制造药物DefenCath 该药物用于减少导管相关血流感染(CRBSI) [1] 产品研发进展 - DefenCath于2023年11月15日获得美国FDA批准 [1] 股票信息 - 公司在纳斯达克上市 股票代码为CRMD [1]

Key Takeaways CorMedix acquired Melinta for $300M, adding seven marketed therapies to its portfolio.The deal boosts 2025 revenue outlook to $325-$350M, with EPS accretion expected in 2026.Rezzayo offers near-term growth and is in phase III testing for expanded fungal infection use.CorMedix (CRMD) has taken a major step toward diversifying its revenue base and reducing reliance on a single product with the recent $300 million acquisition of Melinta Therapeutics. The move significantly expands the company’s m ...

CorMedix Inc. (NASDAQ:CRMD) is one of the best affordable biotech stocks to invest in now. On September 9, Citizens JMP analyst Jason Butler reiterated a Buy rating on CorMedix Inc. (NASDAQ:CRMD) and set a price target of $22.00. Is CorMedix Inc. (CRMD) Among Billionaire Paul Singer’s Top Long-Term Stock Picks? In other news, CorMedix Inc. (NASDAQ:CRMD) announced on September 2 the successful completion of its previously announced acquisition of Melinta Therapeutics LLC. Melinta Therapeutics LLC is a pri ...

Key Takeaways CorMedix stock is up 59.7% YTD, fueled by strong uptake of its FDA-approved drug DefenCath.DefenCath posted $78.8M in H1 2025 revenues, with full-year sales now guided to $200-$215M.CRMD's $300M Melinta buy adds seven drugs, pushing 2025 pro forma revenue outlook to $325-$350M.Shares of CorMedix (CRMD) have soared 59.7% in the year-to-date period. This stock price rally is attributable to significant investor confidence regarding the strong uptake of the company’s lead marketed drug, DefenCath ...

PresentationRoss Cohen Okay. So thank you all for joining. Just a quick note on disclosure. For important disclosures, please see the Morgan Stanley research disclosure website or please reach out to your Morgan Stanley sales representatives for any disclosures. So welcome to the Morgan Stanley Healthcare Conference and then the fireside chat with CorMedix. My name is Ross Cohen. I'm an Executive Director in the Morgan Stanley Healthcare Investment Banking team. And I'm thrilled to be joined in person by Jo ...

PresentationRoss Cohen Okay. So thank you all for joining. Just a quick note on disclosure. For important disclosures, please see the Morgan Stanley research disclosure website or please reach out to your Morgan Stanley sales representatives for any disclosures. So welcome to the Morgan Stanley Healthcare Conference and then the fireside chat with CorMedix. My name is Ross Cohen. I'm an Executive Director in the Morgan Stanley Healthcare Investment Banking team. And I'm thrilled to be joined in person by Jo ...

CorMedix (NasdaqGM:CRMD) FY Conference September 10, 2025 10:45 AM ET Company ParticipantsRoss Cohen - Executive DirectorJoe Todisco - CEORoss CohenOkay. Thank you all for joining. Just a quick note on disclosure. For important disclosures, please see the Morgan Stanley Research Disclosure website, or please reach out to your Morgan Stanley sales representatives for any disclosures. Welcome to the Morgan Stanley Healthcare Conference and the Fireside Chat with CorMedix. My name is Ross Cohen. I'm an Executi ...

The price trend for CorMedix (CRMD) has been bearish lately and the stock has lost 14% over the past week. However, the formation of a hammer chart pattern in its last trading session indicates that the stock could witness a trend reversal soon, as bulls might have gained significant control over the price to help it find support.While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts abou ...

BERKELEY HEIGHTS, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it has made a $5 million strategic minority equity investment in Talphera, Inc. (Nasdaq: TLPH), acquiring 9,090,909 shares at an at-market price of $0.55 per share as part of Talphera’s concurrently announced private placement financing. Talphera expec ...